Novartis has agreed to acquire an experimental breast cancer drug from Synnovation Therapeutics in a deal valued at up to $3 billion, including upfront and milestone payments. The asset targets HR+/HER2- metastatic breast cancer and strengthens Novartis’ oncology pipeline.
"We believe Novartis’s global capabilities and commitment to patients with cancer will accelerate the development of SNV4818 beyond what Synnovation could achieve alone. This acquisition reflects the strength of the Synnovation team and our drug discovery and development capabilities.” — Wenqing Yao, Ph.D, Chief Executive Officer, Synnovation
Nadia Care, formerly Cayaba Care, has raised $12 million to expand its maternal care platform across multiple U.S. states, delivering in-person and virtual support spanning pregnancy through postpartum.
"Nadia Care is challenging the status quo of how maternal care is delivered, stepping in to fill a major gap for mothers and families with care directly from their communities. When you pair that kind of connection with wraparound care and technology, you see improved health outcomes and lower total costs. We're proud to support the Nadia Care team in this exciting next step of their journey." — Anna Haghgooie, Managing Director, Valtruis
🔗 https://www.mobihealthnews.com/news/cayaba-care-rebrands-nadia-care-garners-12m
The University of Auckland is supporting a NZ$5.1 million programme funded by the Matariki Fund to help eliminate cervical cancer across the Pacific, where incidence rates are reported to be up to nine times higher than in Australasia VALANX Biotech has secured €3 million with support from Fujifilm to advance its antibody-drug conjugate programme targeting metastatic triple-negative breast cancer. The round includes new investors Foundation Fournier-Majoie and FUJIFILM Corporation, alongside existing backers xista science ventures, Tecnet Equity, SOSV, and angel investors Urs Spitz and SkyGene.
"As a foundation for innovation in oncology, we back teams with outstanding, scientifically differentiated programs and a clear development path. VALANX’s approach to site-selectable conjugation addresses a central challenge in the ADC field – controlling toxicity to unlock greater efficacy." — Ana Maricevic, Impact Investor, Foundation Fournier-Majoie
A $100,000 grant from Anthem is supporting expanded outreach and services aimed at improving access to women’s health care in Indiana.
"We believe strong communities begin with strong women and families. Our partnership with Women’s Fund builds on our shared commitment to improving health, stability and opportunity for women and girls across the state. When women are supported, families and communities thrive.” — Lynn Scott, Medicaid Plan President, Anthem Blue Cross and Blue Shield in Indiana
Myriad Genetics has received FDA approval for MyChoice CDx as a companion diagnostic, supporting more precise treatment decisions in ovarian cancer care. Marking MyChoice CDx as the only FDA-approved companion diagnostic test in the United States to identify patients with HRD-positive status eligible for treatment with Zejula.
“The FDA approval reinforces Myriad’s long-standing leadership in ovarian cancer diagnostics and underscores the clinical importance of comprehensive HRD testing. By enabling precise identification of patients who may benefit from PARP inhibitors, MyChoice CDx helps ensure that treatment decisions are guided by robust genomic insights.” — Brian Donnelly, Chief Commercial Officer, Myriad Genetics
🔗 https://finance.yahoo.com/news/myriad-genetics-receives-fda-approval-200500038.html
UNFPA and FIGO have signed a new agreement to strengthen collaboration across policy, clinical leadership and investment to advance women’s health globally. Together, the two organizations aim to improve maternal and reproductive health services and advance the elimination of women’s cancers.
“The partnership between UNFPA and FIGO reflects a truth borne out by the evidence: investing in maternal health saves lives, transforms communities, and requires urgent prioritization. This agreement will help us strengthen midwifery and obstetric care models, expand evidence-based maternal health innovations, elevate clinical standards, and mobilize the skills and resources required to deliver measurable impact at scale." — Diene Keita, Executive Director, UNFPA
🔗 https://vir.com.vn/cvg-invests-in-ren-wellness-to-expand-womens-health-portfolio-148163.html
Maven Clinic has launched Maven Intelligence, an AI-powered layer designed to enhance care delivery and coordination across fertility, maternity, parenting and menopause. This announcement builds on AI innovation already embedded across the Maven platform, which have helped accelerate access to care, surface earlier risk signals, reduce administrative burden, and enabling clinicians to focus on higher-impact care.
"AI isn't a feature on the margins of healthcare, it's foundational to how modern care must be delivered. Maven Intelligence brings together a decade of clinical insight and real-world outcomes to turn data into action, enabling earlier intervention, more confident decision-making, and better care for women at every stage of life." — Kate Ryder,founder and CEO, Maven Clinic
Flourish Care has secured $5.7M seed funding to expand its insurance-covered doula model, supporting families through pregnancy, birth and postpartum. The doulas provide birth plan and advocacy support, comfort and pain management, feeding support, sleep guidance, childbirth education and more.
“The policy and payer landscape has finally caught up to what families have always needed. Flourish Care is building the scalable model that will fundamentally integrate doula care into clinical workflows, insurance networks, and women’s lives” — Nasir Qadree, founder and managing partner of Zeal Capital Partners
🔗 https://medcitynews.com/2026/03/flourish-care-doula-seed-funding/
Luna and Kindbody have announced a partnership to bring more personalised, data-driven insights into fertility care, combining wearable data with clinical services. Through this collaboration, Luna’s technology will be made available within the Kindbody ecosystem, enriching the experience for fertility patients seeking a more informed, connected, and supportive path toward parenthood.
“This partnership with Luna represents a significant step forward in making fertility care smarter and more personalized. By leveraging data-driven insights, we can better support patients and providers alike, ensuring every decision is informed, effective, and centered on the needs of those on their fertility journey.” — David Stern, CEO, Kindbody
